GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » Gross-Profit-to-Asset %

Perseus Proteomics (TSE:4882) Gross-Profit-to-Asset % : 4.14% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Perseus Proteomics's annualized Gross Profit for the quarter that ended in Dec. 2023 was 円78.45 Mil. Perseus Proteomics's average Total Assets over the quarter that ended in Dec. 2023 was 円1,893.23 Mil. Therefore, Perseus Proteomics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 4.14%.


Perseus Proteomics Gross-Profit-to-Asset % Historical Data

The historical data trend for Perseus Proteomics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics Gross-Profit-to-Asset % Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 17.87 8.32 7.69 3.07 2.95

Perseus Proteomics Quarterly Data
Mar18 Mar19 Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 3.06 3.94 4.34 4.14

Competitive Comparison of Perseus Proteomics's Gross-Profit-to-Asset %

For the Drug Manufacturers - General subindustry, Perseus Proteomics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perseus Proteomics's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's Gross-Profit-to-Asset % falls into.



Perseus Proteomics Gross-Profit-to-Asset % Calculation

Perseus Proteomics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=86.532/( (3300.53+2566.65)/ 2 )
=86.532/2933.59
=2.95 %

Perseus Proteomics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=78.448/( (1989.786+1796.664)/ 2 )
=78.448/1893.225
=4.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Perseus Proteomics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Perseus Proteomics (TSE:4882) Business Description

Traded in Other Exchanges
N/A
Address
4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines